Alnylam Pharmaceuticals Inc (ALNY)
152.29
-2.04
(-1.32%)
USD |
NASDAQ |
May 08, 16:00
152.37
+0.08
(+0.05%)
Pre-Market: 20:00
Alnylam Pharmaceuticals Revenue (Quarterly): 494.33M for March 31, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 494.33M |
December 31, 2023 | 439.72M |
September 30, 2023 | 750.53M |
June 30, 2023 | 318.75M |
March 31, 2023 | 319.29M |
December 31, 2022 | 335.04M |
September 30, 2022 | 264.31M |
June 30, 2022 | 224.82M |
March 31, 2022 | 213.26M |
December 31, 2021 | 258.54M |
September 30, 2021 | 187.63M |
June 30, 2021 | 220.55M |
March 31, 2021 | 177.57M |
December 31, 2020 | 163.56M |
September 30, 2020 | 125.85M |
June 30, 2020 | 103.96M |
March 31, 2020 | 99.48M |
December 31, 2019 | 71.68M |
September 30, 2019 | 70.06M |
June 30, 2019 | 44.71M |
March 31, 2019 | 33.29M |
December 31, 2018 | 21.03M |
September 30, 2018 | 2.069M |
June 30, 2018 | 29.91M |
March 31, 2018 | 21.90M |
Date | Value |
---|---|
December 31, 2017 | 37.92M |
September 30, 2017 | 17.10M |
June 30, 2017 | 15.93M |
March 31, 2017 | 18.96M |
December 31, 2016 | 17.45M |
September 30, 2016 | 13.65M |
June 30, 2016 | 8.709M |
March 31, 2016 | 7.345M |
December 31, 2015 | 7.551M |
September 30, 2015 | 6.324M |
June 30, 2015 | 8.685M |
March 31, 2015 | 18.54M |
December 31, 2014 | 24.02M |
September 30, 2014 | 10.97M |
June 30, 2014 | 7.295M |
March 31, 2014 | 8.275M |
December 31, 2013 | 10.85M |
September 30, 2013 | 8.991M |
June 30, 2013 | 8.687M |
March 31, 2013 | 18.64M |
December 31, 2012 | 8.495M |
September 30, 2012 | 16.76M |
June 30, 2012 | 20.88M |
March 31, 2012 | 20.59M |
December 31, 2011 | 20.46M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
44.71M
Minimum
Jun 2019
750.53M
Maximum
Sep 2023
244.18M
Average
216.91M
Median
Revenue (Quarterly) Benchmarks
Ionis Pharmaceuticals Inc | 119.50M |
Pfizer Inc | 14.88B |
Blueprint Medicines Corp | 96.12M |
BridgeBio Pharma Inc | 211.12M |
Madrigal Pharmaceuticals Inc | -- |
Revenue (Quarterly) Related Metrics
Net Income (Quarterly) | -65.94M |
Total Expenses (Quarterly) | 537.77M |
EPS Diluted (Quarterly) | -0.52 |
Enterprise Value | 17.91B |
Gross Profit Margin (Quarterly) | 86.65% |
Profit Margin (Quarterly) | -13.34% |
Earnings Yield | -1.76% |
Normalized Earnings Yield | -1.406 |